CAOA: Cannabis Administration and Opportunity Act — Federal Legalization Bill

Executive Summary

The Cannabis Administration and Opportunity Act (CAOA) is a comprehensive federal legalization bill that would remove cannabis entirely from the Controlled Substances Act, establish a federal regulatory framework, and address decades of prohibition-related harms through expungement and social equity provisions. First introduced in July 2021 by Senate Majority Leader Chuck Schumer, Senator Cory Booker, and Senator Ron Wyden, the legislation represents the most ambitious federal cannabis reform proposal ever advanced by congressional leadership. The bill would transfer primary regulatory authority from the Drug Enforcement Administration to the Food and Drug Administration and the Alcohol and Tobacco Tax and Trade Bureau, impose a federal excise tax escalating to 25% over five years, and create pathways for individuals with prior cannabis convictions to have their records expunged. Reintroduced in July 2026 after previous versions stalled in committee, CAOA faces significant political headwinds but remains the benchmark against which all federal legalization proposals are measured.

Unlike incremental reform bills such as the SAFE Banking Act or the MORE Act, CAOA attempts to construct a complete post-prohibition regulatory architecture. The legislation spans hundreds of pages and addresses everything from interstate commerce rules to Small Business Administration loan eligibility for cannabis operators. Its reintroduction in 2026 comes as 38 states have legalized medical cannabis and 24 states permit adult-use sales, creating mounting pressure for federal action to resolve the conflicts between state-legal industries and federal prohibition.

Why This Matters

CAOA would fundamentally reshape the $30 billion U.S. cannabis industry and impact millions of Americans with prior cannabis convictions, while determining whether multi-state operators or small businesses dominate the post-prohibition market. The legislation's passage would immediately affect approximately 15,000 state-licensed cannabis businesses operating in legal limbo, unable to access traditional banking services, claim standard business tax deductions under Internal Revenue Code Section 280E, or transport products across state lines despite operating legally under state law.

For patients, descheduling would resolve the conflict that forces medical cannabis users to choose between their medicine and federal employment, housing assistance, or immigration status. An estimated 5 million registered medical cannabis patients nationwide currently risk federal consequences for using state-legal treatments. Veterans receiving care through the Department of Veterans Affairs face particular hardship, as VA physicians cannot recommend cannabis under current federal law even in states where medical use is legal.

The criminal justice implications are equally profound. According to FBI Uniform Crime Reporting data, law enforcement made over 350,000 cannabis-related arrests in 2024, with possession accounting for the vast majority. CAOA's expungement provisions would create a federal process for clearing these convictions and require federal courts to seal records, though implementation would depend heavily on state cooperation since most cannabis arrests occur at the state and local level.

Financial markets are watching closely. Cannabis companies currently trade on Canadian exchanges or over-the-counter markets because NASDAQ and NYSE have been reluctant to list businesses violating federal law. Descheduling would open major exchange listings, institutional investment, and potentially unlock billions in capital currently sidelined. Multi-state operators like Curaleaf, Green Thumb Industries, Trulieve, and Verano have built operations across dozens of states while operating under the threat that federal enforcement policy could change overnight.

Background and History

CAOA emerged from years of incremental federal reform efforts that failed to achieve comprehensive legalization, representing a strategic shift by Democratic leadership toward an all-encompassing approach rather than piecemeal banking or research bills.

The Pre-CAOA Reform Landscape (2013-2020)

Federal cannabis reform efforts before CAOA focused primarily on narrow fixes to specific prohibition-related problems. The Cole Memorandum, issued by Deputy Attorney General James Cole in August 2013, established prosecutorial discretion guidelines that effectively tolerated state-legal cannabis programs without changing federal law. This policy created the regulatory space for Colorado and Washington to launch adult-use sales in 2014, but provided no statutory protection.

Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, demonstrating the fragility of policy-based approaches. Congress responded with appropriations riders like the Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), which prohibited the Department of Justice from using funds to interfere with state medical cannabis programs. These riders required annual renewal and covered only medical programs, leaving adult-use states unprotected.

The STATES Act, introduced in 2018 by Senators Cory Gardner and Elizabeth Warren, proposed amending the Controlled Substances Act to exempt state-compliant cannabis activity from federal enforcement. The bill attracted bipartisan support and President Trump indicated he would "probably" support it, but it never received a committee vote. Similarly, the Marijuana Justice Act, introduced by Senator Booker in 2017 and reintroduced in 2019, called for complete descheduling but was widely viewed as aspirational rather than viable legislation.

The MORE Act and Its Limitations (2020-2022)

The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, passed by the House of Representatives in December 2020, marked the first time either chamber approved legislation to end federal cannabis prohibition. The bill would have removed cannabis from the Controlled Substances Act and imposed a 5% federal tax, with revenue directed toward communities harmed by the War on Drugs.

Despite this historic House passage, the MORE Act faced criticism for lacking detailed regulatory frameworks. The legislation focused heavily on descheduling and social equity but provided limited guidance on how federal agencies would regulate a legal cannabis market. Senate leadership declined to bring the bill to a vote, citing insufficient Republican support and concerns about the bill's implementation details. The House passed an updated version of the MORE Act again in April 2022, but it similarly stalled in the Senate.

CAOA's First Introduction (July 2021)

On July 14, 2021, Senate Majority Leader Chuck Schumer, Finance Committee Chairman Ron Wyden, and Senator Cory Booker released a discussion draft of CAOA, soliciting public comment before formal introduction. This unusual approach signaled both the bill's ambition and the sponsors' recognition that comprehensive legalization required extensive stakeholder input.

The discussion draft proposed removing cannabis from the Controlled Substances Act entirely within 60 days of enactment, transferring regulatory authority to FDA and the Alcohol and Tobacco Tax and Trade Bureau (TTB), and imposing a federal excise tax starting at 10% and escalating to 25% over five years. The tax structure drew immediate criticism from industry groups who argued it would advantage illicit markets, while social equity advocates praised provisions directing revenue toward communities disproportionately harmed by prohibition.

The draft included detailed provisions on everything from pesticide regulation to trademark protection, attempting to anticipate the practical challenges of transitioning from prohibition to a regulated market. It proposed creating an Office of Cannabis Justice within the Department of Justice to administer grant programs and coordinate expungement efforts.

Formal Introduction and Committee Inaction (2022)

Schumer, Booker, and Wyden formally introduced CAOA as S. 4591 on July 21, 2022, incorporating some feedback from the year-long comment period. The revised bill slightly modified the tax escalation schedule and added provisions addressing concerns from small businesses and craft cultivators about market consolidation.

The legislation was referred to the Senate Finance Committee, where it received no hearings and no markup. Several factors contributed to the bill's stagnation. Midterm election dynamics made controversial votes unappealing. Key moderate Democrats, including Senators Joe Manchin and Kyrsten Sinema, expressed reservations about full legalization. Republican support remained minimal, with most GOP senators favoring more limited reforms like the SAFE Banking Act.

The cannabis industry itself was divided. Large multi-state operators generally supported federal reform but worried about the high tax rates and stringent social equity requirements that might limit their growth. Small operators and social equity applicants feared that descheduling without strong protections would lead to corporate consolidation and the elimination of state-level programs that had created opportunities for diverse ownership.

The 2026 Reintroduction

On July 16, 2026, Senate Democrats reintroduced CAOA with modifications reflecting the changed political and market landscape. The new version adjusts the tax schedule, strengthens interstate commerce provisions, and adds language addressing the proliferation of hemp-derived intoxicating cannabinoids that have emerged under the 2018 Farm Bill's THC loophole. The reintroduction comes as public support for legalization has reached 70% in national polling and as the Biden administration's rescheduling process has stalled in administrative review.

Key Players

Senate Sponsors

Senate Majority Leader Chuck Schumer (D-NY) has made cannabis reform a signature issue, using his leadership position to prioritize the legislation despite limited Republican support. Schumer represents New York, which launched adult-use sales in 2022 and has struggled with slow licensing and market development challenges that inform his approach to federal policy. According to statements released with the 2026 reintroduction, Schumer emphasized that "the federal government's continued prohibition of cannabis is outdated, harmful, and ignores the will of the American people."

Senator Cory Booker (D-NJ) has been Congress's most vocal advocate for centering racial justice in cannabis reform. Booker has repeatedly stated he will not support legalization bills that lack strong social equity provisions and expungement mechanisms. His insistence on these elements has shaped CAOA's comprehensive approach to addressing prohibition's harms, though critics argue his demands have made compromise with Republicans impossible.

Senator Ron Wyden (D-OR), as Finance Committee Chairman, brings tax and regulatory expertise to CAOA's framework. Oregon legalized adult-use cannabis in 2014, giving Wyden a decade of constituent experience with both the benefits and challenges of state-legal markets. Wyden has focused particularly on the tax treatment of cannabis businesses and the need to end 280E restrictions that prevent normal business deductions.

Federal Agencies

The Drug Enforcement Administration currently classifies cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, defined as having no accepted medical use and high abuse potential. DEA has historically opposed rescheduling or descheduling, though the agency's position has softened slightly as it processes the administrative rescheduling to Schedule III initiated by the Department of Health and Human Services in 2023. Under CAOA, DEA would lose primary jurisdiction over cannabis entirely.

The Food and Drug Administration would assume primary regulatory authority under CAOA, overseeing product safety, labeling, and health claims. FDA has taken a cautious approach to cannabis, approving only a handful of cannabis-derived pharmaceuticals (Epidiolex, Marinol, Syndros, Cesamet) while declining to regulate the broader market. The agency has expressed concern about its capacity to suddenly oversee thousands of cannabis products without significant additional resources and statutory clarity.

The Alcohol and Tobacco Tax and Trade Bureau would collect federal cannabis excise taxes and regulate certain aspects of production and distribution, similar to its role in alcohol markets. TTB has not taken public positions on cannabis policy but would require substantial expansion to handle cannabis oversight.

Industry Organizations

The National Cannabis Industry Association, representing hundreds of state-licensed businesses, has generally supported CAOA while advocating for lower tax rates and clearer interstate commerce rules. According to NCIA statements, the organization supports descheduling but warns that the 25% excise tax ceiling could sustain illicit markets in high-tax states.

The U.S. Cannabis Council, which represents larger multi-state operators, has emphasized the need for federal reform to enable normal business operations, including access to capital markets and banking services. The organization has been more willing than NCIA to accept higher taxes in exchange for clear federal legality.

Opposition

Smart Approaches to Marijuana (SAM), led by Kevin Sabet, remains the most prominent national organization opposing legalization. SAM advocates for decriminalization of possession without creating commercial markets, arguing that legalization has increased youth use, impaired driving, and public health harms in states like Colorado. According to SAM's analysis of CAOA, the bill would create "Big Marijuana" modeled on Big Tobacco, prioritizing corporate profits over public health.

Law enforcement organizations, including the National Sheriffs' Association, have historically opposed legalization, though some state and local law enforcement leaders in legal states have adopted more neutral positions. The sheriffs' association has expressed concerns about impaired driving detection and the impact of legalization on communities near borders with prohibition states.

Legal and Regulatory Framework

CAOA would fundamentally restructure federal cannabis law by removing marijuana from the Controlled Substances Act, amending dozens of federal statutes to eliminate cannabis-related penalties, and establishing a new regulatory regime spanning multiple agencies.

Descheduling Mechanism

The bill would amend the Controlled Substances Act, 21 U.S.C. § 801 et seq., to remove "marihuana" from Schedule I within 60 days of enactment. This differs from rescheduling proposals that would move cannabis to Schedule III or Schedule II while maintaining federal control. Complete descheduling would mean cannabis is no longer a controlled substance under federal law, similar to alcohol or tobacco.

The legislation includes conforming amendments to eliminate cannabis from the definition of controlled substances throughout federal law, affecting statutes ranging from immigration law (8 U.S.C. § 1227) to federal employment law. This comprehensive approach attempts to prevent the legal ambiguities that would arise if cannabis were removed from the CSA but still referenced as a controlled substance elsewhere in federal code.

Federal Regulatory Authority

CAOA assigns FDA primary authority to regulate cannabis products for safety, requiring the agency to establish standards for testing, labeling, packaging, and health claims. The bill directs FDA to issue regulations within one year addressing pesticide residues, microbial contaminants, heavy metals, and residual solvents. This timeline has been criticized as unrealistic given FDA's limited cannabis expertise and resource constraints.

The Alcohol and Tobacco Tax and Trade Bureau would regulate cannabis production and distribution similar to its oversight of alcohol, including permitting requirements, record-keeping, and tax collection. TTB would work with FDA to prevent regulatory gaps and overlaps, though the bill provides limited detail on how the agencies would coordinate.

The legislation explicitly preserves state authority to maintain prohibition or establish their own regulatory systems. This federalism approach mirrors alcohol regulation under the 21st Amendment, allowing states like Idaho or Nebraska to maintain complete bans while states like California or Colorado continue their existing programs.

Taxation Structure

CAOA imposes a federal excise tax on cannabis products, starting at 10% of the sale price in year one and escalating by 3% annually until reaching 25% in year six. The tax applies at the point of sale from producer to processor or retailer, not at final consumer purchase. Small producers with annual revenue below $20 million would receive a 50% tax reduction in the first two years.

Revenue from the cannabis tax would be deposited in three trust funds: the Community Reinvestment Trust Fund (40%), the Cannabis Justice Office Fund (40%), and the Substance Abuse Prevention and Treatment Fund (20%). This allocation reflects the bill's emphasis on repairing prohibition-related harms rather than simply generating general revenue.

The tax structure has generated significant debate. Industry analysts note that combined federal and state taxes could exceed 40% in high-tax states like California, where state excise taxes (15%), cultivation taxes, and local taxes already burden legal operators. Critics argue this would perpetuate illicit markets, while supporters contend that tobacco taxes exceeding 50% have not prevented the legal tobacco industry from dominating.

Expungement and Record Sealing

The bill requires federal courts to expunge cannabis convictions and conduct resentencing for individuals currently incarcerated for federal cannabis offenses. The Administrative Office of the U.S. Courts would be required to identify all federal cannabis convictions and initiate expungement proceedings automatically, without requiring individuals to petition.

For state convictions, CAOA authorizes $1 billion in grants to states that establish expungement programs meeting federal standards. The bill cannot mandate state action due to the 10th Amendment, but the grant funding provides a significant incentive. States would be required to make expungement automatic rather than requiring individuals to navigate petition processes.

Interstate Commerce

One of CAOA's most significant provisions explicitly permits interstate commerce in cannabis among states that have legalized. This would override state laws that currently require all cannabis sold in a state to be grown and processed in that state. The bill invokes Congress's authority under the Commerce Clause, Article I, Section 8 of the Constitution, to regulate trade among states.

Allowing interstate commerce would dramatically reshape the industry. Small states like Rhode Island or Delaware could not sustain efficient cultivation operations serving only their in-state markets, while large agricultural states like California could export to the entire country. This provision has created tension between states that have invested in building local industries and those that see interstate commerce as essential to market efficiency.

State-by-State Implications

CAOA's impact would vary dramatically across states depending on their current legal status, with adult-use states gaining banking access and interstate commerce opportunities while prohibition states would face pressure to reconsider their policies as federal prohibition ends.

California

California legalized adult-use cannabis in 2016 and has struggled with high taxes, slow local licensing, and a persistent illicit market. CAOA would eliminate 280E tax burdens that currently prevent California operators from deducting ordinary business expenses, potentially improving profitability for compliant businesses. However, the federal excise tax would add to California's already high tax burden (15% state excise tax plus cultivation taxes plus local taxes), potentially exceeding 40% total. Interstate commerce provisions could benefit California's large cultivation sector by opening export markets, but might also allow cheaper product from lower-cost states to enter California.

New York

New York legalized adult-use sales in 2021 and launched retail operations in 2022, prioritizing social equity applicants for initial licenses. The state has faced challenges with slow licensing, illegal shops operating openly, and limited access to capital for equity licensees. CAOA's banking provisions and SBA loan eligibility would directly address capital access problems that have hampered New York's equity program. The federal social equity grants could supplement New York's existing equity programs, though the state's high cost of operations might limit the impact.

Texas

Texas maintains cannabis prohibition except for a limited low-THC medical program. As a conservative state with significant agricultural capacity, Texas would face a decision under CAOA whether to legalize and capture tax revenue and agricultural opportunities, or maintain prohibition while neighboring states develop cannabis industries. The bill's federalism provisions explicitly allow Texas to maintain prohibition, but economic pressure from surrounding states could influence policy. Texas's large population (30 million) and agricultural expertise make it a potentially dominant cannabis producer if it chooses to legalize.

Colorado

Colorado, the first state to launch adult-use sales in 2014, has a mature market with established operators and regulatory systems. CAOA would benefit Colorado businesses by enabling interstate commerce, allowing the state's experienced operators to expand nationally. However, Colorado's seed-to-sale tracking system and residency requirements for ownership might conflict with federal interstate commerce provisions. The state would need to reconcile its existing regulatory framework with new federal rules, potentially requiring legislative changes.

Florida

Florida has a large medical cannabis program serving over 800,000 registered patients but has not legalized adult-use. A 2024 adult-use ballot initiative failed to reach the 60% threshold required for constitutional amendments in Florida. CAOA would not force Florida to allow adult-use sales, but would eliminate federal barriers to the state's medical program and potentially influence future legalization debates. Florida's large population and tourism industry make it a significant market regardless of adult-use status.

Ohio

Ohio legalized adult-use cannabis through a ballot initiative in 2023, with sales launching in 2024. The state's program includes social equity provisions and allows existing medical dispensaries to serve adult-use customers. CAOA would help Ohio operators access banking and capital, addressing early-stage funding challenges. Interstate commerce could allow Ohio to import product during the market's development phase, preventing shortages that plagued early markets in other states.

Massachusetts

Massachusetts launched adult-use sales in 2018 and has developed a robust market with strong regulatory oversight. The state's Cannabis Control Commission has implemented strict testing requirements and social equity programs. CAOA would align federal law with Massachusetts's existing framework, though the state might need to modify its ban on out-of-state product to comply with interstate commerce provisions. Massachusetts operators have advocated for federal reform to enable expansion beyond the state's borders.

Market and Business Implications

Descheduling would unlock access to traditional banking, capital markets, and business services while eliminating 280E tax penalties, potentially adding 30-40% to operator profit margins and enabling consolidation through normal M&A activity.

Banking and Financial Services

Currently, most banks refuse to serve cannabis businesses due to federal money laundering statutes (18 U.S.C. § 1956, § 1957) that make handling proceeds from federally illegal activity a crime. This forces many cannabis businesses to operate largely in cash, creating security risks, tax compliance challenges, and operational inefficiencies. CAOA would immediately resolve this by removing cannabis from the Controlled Substances Act, eliminating the predicate federal offense that triggers money laundering concerns.

Major banks including JPMorgan Chase, Bank of America, and Wells Fargo have stated they will not enter the cannabis banking market until federal prohibition ends. Descheduling would open these institutions to cannabis clients, dramatically expanding available capital and reducing banking costs. Currently, the few banks serving cannabis businesses charge premium fees (often 3-5% of deposits) to offset perceived compliance risks.

Capital Markets and Investment

Cannabis companies currently cannot list on major U.S. stock exchanges because NASDAQ and NYSE prohibit listing businesses that violate federal law. Multi-state operators trade on the Canadian Securities Exchange or over-the-counter markets, limiting liquidity and institutional investment. CAOA would enable uplisting to major exchanges, potentially increasing valuations and access to capital.

Institutional investors including pension funds, mutual funds, and insurance companies largely avoid cannabis investments due to federal illegality. Descheduling would remove this barrier, potentially unlocking billions in institutional capital. Analysts estimate that major exchange listings could increase cannabis company valuations by 30-50% due to improved liquidity and institutional access.

280E Tax Relief

Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses. Cannabis businesses can deduct cost of goods sold but cannot deduct rent, salaries, marketing, or other normal expenses. This typically results in effective tax rates of 60-80% of gross profit.

CAOA's descheduling would eliminate 280E's application to cannabis, allowing normal business deductions. Industry analysts estimate this would improve operator EBITDA margins by 30-40 percentage points, transforming currently unprofitable businesses into profitable ones overnight. This tax relief would be partially offset by CAOA's new federal excise tax, but most operators would still see significant net benefit.

Interstate Commerce and Market Consolidation

Current state laws requiring in-state cultivation and processing fragment the national market into 38+ separate state markets. This prevents economies of scale and forces operators to build redundant infrastructure in each state. CAOA's interstate commerce provisions would enable national supply chains, allowing cultivation in low-cost states and distribution nationwide.

Industry analysts predict interstate commerce would lead to significant market consolidation. Large multi-state operators with capital and infrastructure could acquire smaller operators and consolidate cultivation in a few optimal locations. States with favorable climate and low operating costs—particularly California's Central Valley, Oregon's Willamette Valley, and agricultural regions of Colorado—would likely become dominant production centers.

This consolidation concerns small operators and social equity advocates who fear corporate dominance would eliminate opportunities for diverse ownership. Some states have indicated they would resist interstate commerce provisions by maintaining local sourcing requirements, though the legal viability of such requirements under CAOA's Commerce Clause framework is uncertain.

Intellectual Property

Federal trademark protection is currently unavailable for cannabis products because the Lanham Act (15 U.S.C. § 1051 et seq.) prohibits registering marks for goods that violate federal law. This has prevented brand protection and enabled widespread trademark infringement. CAOA would open federal trademark registration, allowing cannabis businesses to protect brand names, logos, and product identities.

Patent protection for cannabis genetics and cultivation methods is theoretically available now but rarely pursued due to the requirement to disclose federally illegal activity. Descheduling would normalize patent filings, potentially leading to intellectual property disputes over strain genetics and extraction methods. Some advocates worry this could enable corporate control over cannabis genetics that have been developed by underground breeders over decades.

What Experts Say

Policy analysts note that CAOA represents the most comprehensive federal legalization proposal ever seriously considered, but faces significant political obstacles. According to the Brookings Institution's analysis of previous versions, the bill's ambition is both its strength and weakness—it addresses nearly every aspect of prohibition but creates numerous points of contention that make consensus difficult.

The RAND Corporation's Drug Policy Research Center has analyzed CAOA's tax structure and concluded that the escalating excise tax could sustain illicit markets if not carefully implemented. RAND researchers recommend that federal taxes remain below 20% and that implementation be phased to allow legal markets to establish price competitiveness before high taxes take effect.

Constitutional law scholars generally agree that CAOA's Commerce Clause basis for permitting interstate commerce is sound, though states might challenge specific provisions. The Congressional Research Service issued a report in 2023 concluding that Congress has clear authority to deschedule cannabis and regulate interstate commerce, but that states retain authority to prohibit intrastate activity under the 10th Amendment.

Public health researchers have expressed mixed views. The American Public Health Association supports descheduling combined with strong regulatory oversight, emphasizing the need for restrictions on marketing to youth, potency limits, and impaired driving enforcement. Other public health voices, including some pediatricians' groups, have called for more research before full commercialization.

Social equity advocates emphasize that legalization without strong equity provisions could replicate the alcohol and tobacco industries' patterns of corporate consolidation and marketing to vulnerable communities. The Minority Cannabis Business Association has stated that CAOA's equity provisions are necessary but insufficient without significant implementation funding and state-level complementary policies.

What's Next

CAOA faces a difficult path to passage in 2026, requiring 60 Senate votes to overcome a filibuster and navigating a divided Congress where Republicans control the House and cannabis reform remains a low priority amid competing legislative demands.

The bill has been referred to the Senate Finance Committee, where Chairman Wyden could schedule hearings and markup. However, committee action is unlikely before the August recess, and the legislative calendar fills quickly in election years. The 2026 midterm elections in November will dominate congressional attention from September onward, leaving a narrow window for action.

Even if CAOA advances through committee, it would need 60 votes to overcome a Senate filibuster. Democrats currently hold 51 Senate seats (including independents who caucus with Democrats), meaning at least 9 Republicans would need to support the bill. Few Republican senators have endorsed full legalization, though some support more limited reforms like the SAFE Banking Act or rescheduling.

The House of Representatives, currently under Republican control, presents additional challenges. House leadership has not indicated willingness to bring comprehensive legalization to a vote, though the chamber has passed cannabis reform bills when Democrats held the majority. A discharge petition could force a floor vote without leadership support, but this requires 218 signatures and has rarely succeeded on controversial legislation.

Alternative scenarios include breaking CAOA into smaller bills addressing specific issues like banking, expungement, or tax reform. The SAFE Banking Act, which would protect banks serving state-legal cannabis businesses without descheduling cannabis, has passed the House seven times but stalled in the Senate partly because reform advocates like Senator Booker insist on comprehensive legislation rather than piecemeal fixes.

The administrative rescheduling process initiated by the Department of Health and Human Services in 2023 continues in parallel. If DEA completes rescheduling to Schedule III, some pressure for legislative action might decrease, though rescheduling would not address most of the issues CAOA tackles. Schedule III status would end 280E tax penalties but would not permit interstate commerce, open banking fully, or address criminal justice issues.

State-level developments will continue regardless of federal action. Several states have legalization initiatives on the 2026 ballot, and state legislatures in conservative states are increasingly debating medical cannabis programs. This state-level momentum creates ongoing pressure for federal reform but also reduces urgency since state-legal markets continue expanding without federal approval.

Further Reading

• Full text of S. 4591, Cannabis Administration and Opportunity Act (2022 version): https://www.congress.gov/bill/117th-congress/senate-bill/4591
• Congressional Research Service Report: "Marijuana: Medical and Retail—Selected Legal Issues": https://crsreports.congress.gov
• Drug Enforcement Administration, Drug Scheduling: https://www.dea.gov/drug-information/drug-scheduling
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.law.cornell.edu/uscode/text/21/chapter-13
• RAND Corporation, "Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions": https://www.rand.org/pubs/research_reports/RR864.html
• Brookings Institution, "The Cannabis Policy Gap: Federal Prohibition vs. State Legalization": https://www.brookings.edu/articles/the-cannabis-policy-gap/
• National Conference of State Legislatures, "State Medical Cannabis Laws": https://www.ncsl.org/health/state-medical-cannabis-laws
• Senate Finance Committee hearing records on cannabis taxation: https://www.finance.senate.gov
• Food and Drug Administration, "FDA Regulation of Cannabis and Cannabis-Derived Products": https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products